Floatz logo

cd4+/cd25+ cells

Hodgkin's Disease

Masonic Cancer Center, University of MinnesotaCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Hodgkin's Disease cohort.

Asset / SponsorPhaseRating
PEGFILGRASTIM
Michael Spinner, MD
Phase 3BB
Benadryl
City of Hope Medical Center
Phase 2BB
PENTOSTATIN
St. Jude Children's Research Hospital
Phase 3BB
Basiliximab
City of Hope Medical Center
Phase 2BB
Umbilical Cord Blood Cell Infusion
Mesoblast, Ltd.
Phase 3B

View all 30 →

Same molecule, other indications

cd4+/cd25+ cells is also rated in:

AMLDormant
D
Indicative ·
30 / 100
View asset →
Leukemia, Lymphocytic, AcuteDormant
D
Indicative ·
30 / 100
View asset →
Leukemia, Myeloid, ChronicDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →